Cardiovascular

Mouse studies suggest inhibiting TRPM2 could help treat cerebral ischemia/reperfusion injury. In a mouse model of cerebral ischemia/reperfusion injury, systemic TRPM2 knockout decreased infarct size and increased mobility-related neurological scores compared with normal TRPM2 expression. In another mouse model of cerebral ischemia/reperfusion injury, administration of Cymbalta duloxetine, an inhibitor TRPM2 activation, decreased infarct size and increased mobility-related neurological scores compared with vehicle. Next steps could include testing the safety of Cymbalta in mouse models of cerebral ischemia/reperfusion injury...